Log in
Enquire now
‌

US Patent 10894819 Compositions and methods for treating HIV/AIDS with immunotherapy

Patent 10894819 was granted and assigned to Lentigen on January, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Lentigen
Lentigen
Current Assignee
Lentigen
Lentigen
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10894819
Patent Inventor Names
Dina Schneider0
Boro Dropulic0
Kim Anthony Gonda0
Rimas Orentas0
Date of Patent
January 19, 2021
Patent Application Number
16228077
Date Filed
December 20, 2018
Patent Citations Received
‌
US Patent 12024554 Compositions and methods for treating HIV/AIDS with immunotherapy
0
Patent Primary Examiner
‌
Janet L Epps-Smith
Patent abstract

Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10894819 Compositions and methods for treating HIV/AIDS with immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.